Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study

Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study

BackgroundWe investigated the clinical and endoscopic features, management strategies, and outcomes of Chinese cancer patients with immune checkpoint inhibitor (ICI)-induced colitis.MethodThis single-centre retrospective study included patients who developed ICI-induced colitis and underwent endosco...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Furong Kou, Jian Li, Yanshuo Cao, Zhi Peng, Ting Xu, Lin Shen, Jifang Gong, Xicheng Wang
Formato:	Artigo
Idioma:	English
Publicado em:	Frontiers Media S.A. 2023-11-01
Colecção:	Frontiers in Oncology
Assuntos:	immune checkpoint inhibitor colitis endoscopy steroid infliximab rechallenge
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1285478/full

Registos relacionados

Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
Por: Hamzah Abu-Sbeih, et al.
Publicado em: (2018-09-01)

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
Por: Hamzah Abu-Sbeih, et al.
Publicado em: (2019-04-01)

Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
Por: Sae Ohwada, et al.
Publicado em: (2022-06-01)

Immune checkpoint inhibitors and renal toxicity
Por: F. Bocchi, et al.
Publicado em: (2024-06-01)

Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical cases
Por: Ocepek Andreja
Publicado em: (2024-03-01)

Gut microbiome and checkpoint inhibitor colitis
Por: Kanika Sehgal, et al.
Publicado em: (2021-10-01)

Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Por: Hao Chi Zhang, et al.
Publicado em: (2019-02-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
Por: Eva Zhang, et al.
Publicado em: (2021-05-01)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
Por: Ayaka Kaneoka, et al.
Publicado em: (2022-02-01)

Checkpoint Inhibitor-Induced Colitis: An Update
Por: Giuseppe Losurdo, et al.
Publicado em: (2023-05-01)

Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis
Por: Jiahui Cao, et al.
Publicado em: (2024-12-01)

Management and treatment of distal ulcerative colitis
Por: Andrea Calafiore, et al.
Publicado em: (2013-12-01)

Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta‐Analysis
Por: Huijun Xu, et al.
Publicado em: (2024-10-01)

Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
Por: Carmen Portenkirchner, et al.
Publicado em: (2021-04-01)

Analysis of the disease activity of ulcerative colitis with and without concomitant primary sclerosing cholangitis: An investigation using a nationwide database in Japan
Por: Kota Yano, et al.
Publicado em: (2022-01-01)

The growing potential of tofacitinib in immune checkpoint inhibitor-induced colitis: identifying remaining puzzle pieces
Por: Raffaele Pellegrino, et al.
Publicado em: (2024-11-01)

Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors
Por: Guoqiang PAN, et al.
Publicado em: (2019-12-01)

INFLIXIMAB IN THE TREATMENT OF SEVERE STEROID-REFRACTORY ULCERATIVE COLITIS – A CASE REPORT
Por: Darja Urlep, et al.
Publicado em: (2004-04-01)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
Por: Xue Chen, et al.
Publicado em: (2022-05-01)

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
Por: Hamzah Abu-Sbeih, et al.
Publicado em: (2018-12-01)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
Por: Aaron G. Issac, et al.
Publicado em: (2022-06-01)

Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic
Por: Steph A. Pang, et al.
Publicado em: (2023-08-01)

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
Por: Guanzhou Zhou, et al.
Publicado em: (2022-10-01)

Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice
Por: Clarice Ho, et al.
Publicado em: (2024-06-01)

Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis
Por: Qing Zhao, et al.
Publicado em: (2021-09-01)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
Por: Harm Westdorp, et al.
Publicado em: (2021-10-01)

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
Por: Yinghong Wang, et al.
Publicado em: (2018-05-01)

Long-term infliximab therapy for ulcerative colitis in real clinical practice
Por: O V Knyazev, et al.
Publicado em: (2016-08-01)

Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
Por: Margaret Corrigan, et al.
Publicado em: (2019-05-01)

Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab Pioderma gangrenoso asociado a colitis ulcerosa: respuesta a infliximab
Por: A. López San Román, et al.
Publicado em: (2004-06-01)

Immune checkpoint inhibitor colitis, a rising issue in targeted cancer therapy era: A literature review
Por: Adiwinata Randy, et al.
Publicado em: (2024-09-01)

Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review
Por: Hao Zhang, et al.
Publicado em: (2024-01-01)

Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis
Por: Alorfi NM, et al.
Publicado em: (2022-08-01)

Bell's palsy during rechallenge of immune checkpoint inhibitor
Por: Kohji Takemura, et al.
Publicado em: (2023-03-01)

Checkpoint inhibitor induced esophagitis with documented resolution on infliximab
Por: Frank W. Chen, et al.
Publicado em: (2020-12-01)

Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
Por: Ruben Faelens, et al.
Publicado em: (2021-10-01)

Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis
Por: Kata Szemes, et al.
Publicado em: (2020-01-01)

Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
Por: Robert S. Zhang, et al.
Publicado em: (2021-03-01)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
Por: Yasunori Murata, MD, PhD, et al.
Publicado em: (2023-12-01)

Risk Factors and Prognostic Analysis of Immune Checkpoint Inhibitor-Related Colitis in Lung Cancer
Por: Wang S, et al.
Publicado em: (2024-10-01)